Correct stimulation of CD28H arms NK cells against tumor cells.
Journal
European journal of immunology
ISSN: 1521-4141
Titre abrégé: Eur J Immunol
Pays: Germany
ID NLM: 1273201
Informations de publication
Date de publication:
05 Aug 2024
05 Aug 2024
Historique:
revised:
25
07
2024
received:
14
11
2023
accepted:
26
07
2024
medline:
5
8
2024
pubmed:
5
8
2024
entrez:
5
8
2024
Statut:
aheadofprint
Résumé
Tumor evasion has recently been associated with a novel member of the B7 family, HERV-H LTR-associating 2 (HHLA2), which is mostly overexpressed in PDL-1
Identifiants
pubmed: 39101623
doi: 10.1002/eji.202350901
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2350901Subventions
Organisme : SANOFI iAward
Organisme : French minister of research
ID : BPI EFFI-CLIN PSPC
Organisme : ANR project KTD-innov
ID : ANR-17-RHUS-0010
Organisme : LabEX IGO
ID : ANR-11-LABX-0016
Informations de copyright
© 2024 The Author(s). European Journal of Immunology published by Wiley‐VCH GmbH.
Références
Mager, D. L., Hunter, D. G., Schertzer, M. and Freeman, J. D., Endogenous retroviruses provide the primary polyadenylation signal for two new human genes (HHLA2 and HHLA3). Genomics 1999. 59: 255–263.
Janakiram, M., Chinai, J. M., Fineberg, S., Fiser, A., Montagna, C., Medavarapu, R. et al., Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. Clin. Cancer Res. 2015. 21: 2359–2366.
Wang, B., Ran, Z., Liu, M. and Ou, Y., Prognostic Significance of potential immune checkpoint member HHLA2 in human tumors: a comprehensive analysis. Front. Immunol. 2019. 10: 1573.
Bhatt, R. S., Berjis, A., Konge, J. C., Mahoney, K. M., Klee, A. N., Freeman, S. S. et al., KIR3DL3 is an inhibitory receptor for HHLA2 that mediates an alternative immunoinhibitory pathway to PD1. Cancer Immunol. Res. 2021. 9: 156–169.
Zhu, Y., Yao, S., Iliopoulou, B. P., Han, X., Augustine, M. M., Xu, H. et al., B7‐H5 costimulates human T cells via CD28H. Nat. Commun. 2013. 4: 2043–2043.
Zhuang, X. and Long, E. O., CD28 homolog is a strong activator of natural killer cells for lysis of B7H7+ tumor cells. Cancer Immunol. Res. 2019. 7: 939–951.
Wei, Y., Ren, X., Galbo Jr, P. M., Moerdler, S., Wang, H., Sica, R. A. et al., KIR3DL3‐HHLA2 is a human immunosuppressive pathway and a therapeutic target. Sci. Immunol. 2021. 6.
Crespo, J., Vatan, L., Maj, T., Liu, R., Kryczek, I. and Zou, W., Phenotype and tissue distribution of CD28H+ immune cell subsets. Oncoimmunology 2017. 6: e1362529.
Palmer, W. H., Leaton, L. A., Codo, A. C., Crute, B., Roest, J., Zhu, S. et al., Polymorphic KIR3DL3 expression modulates tissue‐resident and innate‐like T cells. Sci. Immunol. 2023. 8: eade5343.
Trundley, A. E., Hiby, S. E., Chang, C., Sharkey, A. M., Santourlidis, S., Uhrberg, M. et al., Molecular characterization of KIR3DL3. Immunogenetics 2006. 57: 904–916.
Ramaswamy, M., Kim, T., Jones, D. C., Ghadially, H., Mahmoud, T. I., Garcia, A. et al., Immunomodulation of T‐ and NK‐cell responses by a bispecific antibody targeting CD28 homolog and PD‐L1. Cancer Immunol. Res. 2022. 10: 200–214.
Zhuang, X. and Long, E. O., NK cells equipped with a chimeric antigen receptor that overcomes inhibition by HLA class I for adoptive transfer of CAR‐NK cells. Front. Immunol. 2022. 13: 840844.
Alchahin, A. M., Mei, S., Tsea, I., Hirz, T., Kfoury, Y., Dahl, D. et al., A transcriptional metastatic signature predicts survival in clear cell renal cell carcinoma. Nat. Commun. 2022. 13: 5747.
Bryceson, Y. T., March, M. E., Ljunggren, H. G. and Long, E. O., Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 2006. 107: 159–166.
Boles, K. S., Barchet, W., Diacovo, T., Cella, M. and Colonna, M., The tumor suppressor TSLC1/NECL‐2 triggers NK‐cell and CD8+ T‐cell responses through the cell‐surface receptor CRTAM. Blood 2005. 106: 779–786.
Campbell, A. R., Regan, K., Bhave, N., Pattanayak, A., Parihar, R., Stiff, A. R. et al., Gene expression profiling of the human natural killer cell response to Fc receptor activation: unique enhancement in the presence of interleukin‐12. BMC Med. Genomics 2015. 8: 66.
Sabry, M., Zubiak, A., Hood, S. P., Simmonds, P., Arellano‐Ballestero, H., Cournoyer, E. et al., Tumor‐ and cytokine‐primed human natural killer cells exhibit distinct phenotypic and transcriptional signatures. Plos One 2019. 14: e0218674.
Romee, R., Lenvik, T., Wang, Y., Walcheck, B., Verneris, M. R. and Miller, J. S., ADAM17, a novel metalloproteinase, mediates CD16 and CD62L shedding in human NK cells and modulates IFNγ responses. Blood 2011. 118: 2184–2184.
Ndhlovu, L. C., Lopez‐Vergès, S., Barbour, J. D., Jones, R. B., Jha, A. R., Long, B. R. et al.. Tim‐3 marks human natural killer cell maturation and suppresses cell‐mediated cytotoxicity. Blood. 2012;119: 3734–3743.
Zamai, L., Ahmad, M., Bennett, I. M., Azzoni, L., Alnemri, E. S. and Perussia, B., Natural killer (NK) cell–mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J. Exp. Med. 1998. 188: 2375–2380.
Palmer, W. H., Leaton, L. A., Codo, A. C., Hume, P. S., Crute, B., Stone, M. et al., Polymorphic KIR3DL3 expression modulates tissue‐resident and innate‐like T cells. Biorxiv 2022. 2022.08.17.503789.
Alter, G., Malenfant, J. M. and Altfeld, M., CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Meth. 2004. 294: 15–22.
Lee, N., Llano, M., Carretero, M., Ishitani, A., Navarro, F., López‐Botet, M. et al., HLA‐E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc. Nat. Acad. Sci. 1998. 95: 5199–5204.
Tang, F., Li, J., Qi, L., Liu, D., Bo, Y., Qin, S. et al., A pan‐cancer single‐cell panorama of human natural killer cells. Cell 2023. 186: 4235–4251. e20.
Cao, Y., Wang, X., Jin, T., Tian, Y., Dai, C., Widarma, C. et al., Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy. Signal Transduct. Target. Ther. 2020. 5: 250.
Pinto, S., Pahl, J., Schottelius, A., Carter, P. J. and Koch, J., Reimagining antibody‐dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers. Trends Immunol. 2022. 43: 932–946.
Gauthier, L., Morel, A., Anceriz, N., Rossi, B., Blanchard‐Alvarez, A., Grondin, G. et al., Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity. Cell. 2019. 177: 1701–1713. e16.
Watkins‐Yoon, J., Guzman, W., Oliphant, A., Haserlat, S., Leung, A., Chottin, C. et al., CTX‐8573, an innate‐cell engager targeting BCMA, is a highly potent multispecific antibody for the treatment of multiple myeloma. Blood 2019. 134: 3182–3182.
André, P., Denis, C., Soulas, C., Bourbon‐Caillet, C., Lopez, J., Arnoux, T. et al., Anti‐NKG2A mAb is a checkpoint inhibitor that promotes anti‐tumor immunity by unleashing both T and NK cells. Cell. 2018. 175: 1731–1743. e13.
Mallone, R., Funaro, A., Zubiaur, M., Baj, G., Ausiello, C. M., Tacchetti, C. et al., Signaling through CD38 induces NK cell activation. Int. Immunol. 2001. 13: 397–409.
Yu, X., Chan, H. T. C., Orr, C. M., Dadas, O., Booth, S. G., Dahal, L. N et al., Complex interplay between epitope specificity and isotype dictates the biological activity of anti‐human CD40 antibodies. Cancer Cell 2018. 33: 664–675. e4.
Zhang, P., Tu, G. H., Wei, J., Santiago, P., Larrabee, L. R., Liao‐Chan, S. et al., Ligand‐blocking and membrane‐proximal domain targeting anti‐OX40 antibodies mediate potent T cell‐stimulatory and anti‐tumor activity. Cell Reports 2019. 27: 3117–3123. e5.
Barrow, A. D., Edeling, M. A., Trifonov, V., Luo, J., Goyal, P., Bohl, B. et al., Natural killer cells control tumor growth by sensing a growth factor. Cell 2018. 172: 534–548. e19.
Zhao, R., Chinai, J. M., Buhl, S., Scandiuzzi, L., Ray, A., Jeon, H. et al., HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T‐cell function. Proc. Nat. Acad. Sci. 2013. 110: 9879–9884.
Böttcher, J. P., Bonavita, E., Chakravarty, P., Blees, H., Cabeza‐Cabrerizo, M., Sammicheli, S. et al., NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 2018. 172: 1022–1037. e14.
Trotta, A. M., Santagata, S., Zanotta, S., D'Alterio, C., Napolitano, M., Rea, G. et al., Mutated Von Hippel‐Lindau‐renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity. J Exp Clin Cancer Res 2018. 37: 297.
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R. and Salzberg, S. L., TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol 2013. 14: R36.
Trapnell, C., Roberts, A., Goff, L., Pertea, G., Kim, D., Kelley, D. R. et al., Differential gene and transcript expression analysis of RNA‐seq experiments with TopHat and Cufflinks. Nat Protoc 2012. 7: 562–578.
Lun, A. T. L., Chen, Y. and Smyth, G. K., It's DE‐licious: a recipe for differential expression analyses of RNA‐seq experiments using quasi‐likelihood methods in edgeR. Meth. Mol. Biol. Clifton N J. 2016. 1418: 391–416.
Hochberg, Y. and Benjamini, Y.. More powerful procedures for multiple significance testing. Statist. Med. 1990. 9: 811–818.
Walter, W., Sánchez‐Cabo, F. and Ricote, M.. GOplot: an R package for visually combining expression data with functional analysis. Bioinformatics 2015;31: 2912–2914.
Vidard, L., Dureuil, C., Baudhuin, J., Vescovi, L., Durand, L., Sierra, V. et al., CD137 (4‐1BB) engagement fine‐tunes synergistic IL‐15– and IL‐21–driven NK cell proliferation. J. Immunol. 2019. 203: 676–685.